Ocrelizumab (Ocrevus)

Covered: Ocrevus (ocrelizumab) is covered for adults (≥18) with FDA‑approved relapsing forms of MS (clinically isolated syndrome, relapsing‑remitting MS, active secondary progressive MS) and primary progressive MS; treatments outside FDA‑approved indications, age limits, or unmet safety criteria are excluded. Key requirements: prescription or consultation by an MS specialist/neurologist, documentation of diagnosis and age, adherence to dosing (300 mg IV then 300 mg 2 weeks later or 600 mg IV every 6 months), and approval is granted for 12 months (initial and renewal).

"Ocrevus is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis (MS)."

Sign up to see full coverage criteria, indications, and limitations.